JUNSHI BIO (688180.SH): FDA Approves Clinical Trial Application for JS212 for the Treatment of Advanced Solid Tumors

16:01 14/12/2025

Kingen Biotech (688180.SH) announced that the company has received a notification from the U.S. Food and Drug Administration (FDA) that its EGFR/HER3 bispecific antibody-drug conjugate (code: JS212) for the treatment of advanced solid tumors has been approved for clinical trial application by the FDA.

JUNSHI BIO (688180.SH) announced that the company has received a notification from the Food and Drug Administration (FDA) of the United States. The clinical trial application for the EGFR/HER3 bispecific antibody-drug conjugate (code: JS212) for the treatment of advanced solid tumors has been approved by the FDA.

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"